home / stock / oryzf / oryzf short
Short Information | Oryzon Genomics S.A. (OTCMKTS:ORYZF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 6,754 |
Total Actual Volume | 6,754 |
Short Trends | |
---|---|
Cover Days | 0 |
Short Days | 7 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 338 |
Average Short Percentage | 35.00% |
Is there a ORYZF Short Squeeze or Breakout about to happen?
See the ORYZF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
03-13-2024 | $2.2 | $2.2 | $2.2 | $2.2 | 300 | 300 | 100% |
03-29-2023 | $2.45 | $2.45 | $2.45 | $2.45 | 204 | 204 | 100% |
03-14-2023 | $2.45 | $2.45 | $2.45 | $2.45 | 750 | 750 | 100% |
06-28-2021 | $4.67 | $4.67 | $4.67 | $4.67 | 200 | 200 | 100% |
05-06-2021 | $4.18 | $4.18 | $4.18 | $4.18 | 4,000 | 4,000 | 100% |
05-05-2021 | $4.15 | $4.15 | $4.15 | $4.15 | 300 | 300 | 100% |
03-11-2021 | $4.6 | $4.6 | $4.6 | $4.6 | 1,000 | 1,000 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Oryzon Genomics S.A. Company Name:
ORYZF Stock Symbol:
OTCMKTS Market:
Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed strong antileukemic activity A third cohort is ongoing following FDA’s OPTIMUS guidance MADRID and CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Oryzon G...
The Phase IIa study ALICE evaluated the combination of iadademstat plus azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) The combination showed substantial antileukemic activity with deep responses and a manageable safety profile, including in patients with...
BIO International Convention 2024 European Hematology Association (EHA) 2024 European Network to Cure ALS (ENCALS) 2024 MADRID and CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical ...